The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterization of tumor mutational burden (TMB), PD-L1, and DNA repair genes to assess correlation with immune checkpoint inhibitors (ICIs) response in metastatic renal cell carcinoma (mRCC).
 
Matthew Labriola
No Relationships to Disclose
 
Jason Zhu
Consulting or Advisory Role - Bayer
Travel, Accommodations, Expenses - UroToday
 
Rajan Gupta
Honoraria - Bayer Schering Pharma; InvivoCorp
Consulting or Advisory Role - Bard Medical; Bayer Schering Pharma; InvivoCorp
Speakers' Bureau - Bayer Schering Pharma
 
Shannon McCall
No Relationships to Disclose
 
Jennifer Jackson
Employment - Personal Genome Diagnostics
 
James R White
Employment - Resphera Biosciences
Leadership - Resphera Biosciences
Stock and Other Ownership Interests - Resphera Biosciences
Consulting or Advisory Role - Personal Genome Diagnostics
Patents, Royalties, Other Intellectual Property - Personal Genome Diagnostics
 
Elizabeth Weingartner
Employment - Personal Genome Diagnostics
 
Eric Kong
Employment - Personal Genome Diagnostics
 
Peter Simone
Employment - Personal Genome Diagnostics
 
Eniko Papp
Employment - Personal Genome Diagnostics
 
Kelly Gerding
Employment - Personal Genome Diagnostics
 
John Simmons
Employment - Personal Genome Diagnostics
Stock and Other Ownership Interests - Personal Genome Diagnostics
 
Daniel J. George
Honoraria - Bayer; Exelixis; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Merck; Pfizer; Sanofi
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Honoraria - Exelixis; Genentech/Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Pfizer; Pharmacyclics; Sanofi
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Genzyme
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merck (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma